Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DORZOLAMIDE HYDROCHLORIDE vs ACETAZOLAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,Adjunctive therapy with beta-blockers in patients with open-angle glaucoma or ocular hypertension
Edema due to congestive heart failure (adjunctive therapy),Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Chronic simple (open-angle) glaucoma,Secondary glaucoma,Preoperative lowering of intraocular pressure in acute angle-closure glaucoma,Altitude sickness (prevention and treatment),Off-label: Idiopathic intracranial hypertension, metabolic alkalosis, sleep apnea, bipolar disorder, cystinuria, hypokalemic periodic paralysis
One drop of 2% solution in the affected eye(s) three times daily.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Terminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
Dorzolamide is metabolized primarily by hepatic cytochrome P450 enzymes, specifically CYP2C9, to N-desethyl-dorzolamide. It forms N-acetylated metabolites as well as the N-desethyl metabolite. Minor renal elimination of unchanged drug occurs.
Primarily excreted unchanged in urine (70-100%). Minor metabolism via hydrolysis of acetyl group (possibly by plasma esterases) to acetazolamide, and glucuronide conjugation.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Approximately 33% bound to plasma proteins, primarily albumin.
~70–90% bound primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
Wide distribution: apparent Vd is approximately 0.53 L/kg; extensive binding to carbonic anhydrase in red blood cells and tissues.
0.2–0.3 L/kg; concentrates in tissues with high carbonic anhydrase content (RBCs, kidneys, eyes).
Topical ophthalmic: systemic absorption is minimal (approximately 2-4% of administered dose reaches systemic circulation due to nasolacrimal drainage and ocular absorption).
Oral: ~100% (well absorbed); IV: 100%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild to moderate impairment; use with caution.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: avoid use (ineffective).
No specific dose adjustment required based on Child-Pugh classification; however, use with caution in severe hepatic impairment due to potential for systemic accumulation.
Child-Pugh class A: no adjustment; Child-Pugh class B-C: caution, reduce dose by 50% and monitor for encephalopathy.
Safety and efficacy not established in pediatric patients. No standard weight-based dosing guidelines available. Some sources recommend the same adult dose (one drop of 2% solution three times daily) for children aged ≥2 years; use with caution.
Children: 5-10 mg/kg/dose orally or IV every 8-12 hours; maximum 500 mg/dose.
No specific dose adjustment required, but elderly patients may be more susceptible to systemic effects; monitor for ocular irritation and electrolyte imbalance.
Initiate at lowest effective dose (250 mg daily) due to increased risk of electrolyte disturbances and renal impairment.
None
WARNING: Metabolically induced acidosis. Use with caution in patients with hepatic cirrhosis to avoid precipitation of hepatic encephalopathy. Not recommended for long-term use in patients with chronic noncongestive angle-closure glaucoma due to risk of increased intraocular pressure with lens displacement.
Sulfonamide hypersensitivity: Dorzolamide is a sulfonamide derivative; cross-reactivity may occur. Discontinue if signs of serious hypersensitivity reactions develop.,Corneal edema and endothelial decompensation: Use with caution in patients with compromised corneas (e.g., low endothelial cell count).,Ocular effects: Transient blurred vision, burning, stinging, and superficial punctate keratitis may occur.,Potential for metabolic acidosis: Carbonic anhydrase inhibitors can cause metabolic acidosis; use with caution in patients with renal impairment or those on concomitant topiramate or acetazolamide.,Bacterial keratitis: Risk with contaminated multidose containers.
Sulfonamide hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue at first sign of rash,Metabolic acidosis - monitor electrolytes, use with caution in patients with respiratory acidosis or those at risk,Hepatic impairment - contraindicated in cirrhosis; may precipitate hepatic encephalopathy,Renal impairment (Cr Cl <10 m L/min) - ineffective and may cause metabolic acidosis,Hematologic reactions (agranulocytosis, aplastic anemia) - monitor CBC,Hypercalciuria and renal stone formation - ensure adequate hydration,Drowsiness, confusion, fatigue - impaired ability to drive/operate machinery,Use in pregnancy - potential risk; cross-sensitivity with sulfonamides
Hypersensitivity to dorzolamide hydrochloride or any component of the formulation,Severe renal impairment (creatinine clearance < 30 m L/min),Hyperchloremic acidosis
Hypersensitivity to acetazolamide or any sulfonamide derivative,Severe hepatic cirrhosis or hepatic impairment,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Adrenocortical insufficiency (Addison's disease),Long-term use in chronic noncongestive angle-closure glaucoma,Metabolic acidosis
None known. No dietary restrictions are required with topical dorzolamide use.
Avoid high doses of vitamin C or cranberry juice as they may acidify urine and decrease drug effectiveness. Maintain adequate hydration; no specific food restrictions.
Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (rabbit) and 20 mg/kg/day (rat). Low systemic absorption (≈4% of ocular dose) minimizes fetal exposure. FDA Pregnancy Category C. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. No specific trimester risks.
First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause fetal metabolic acidosis, electrolyte disturbances, and growth retardation.
It is not known whether dorzolamide is excreted in human milk. Systemic absorption is low (≈4%). Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. M/P ratio not available. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for dorzolamide and potential adverse effects on the breastfed child.
Excreted into breast milk (M/P ratio approximately 0.25). Not recommended due to risk of sulfonamide-related adverse effects (e.g., kernicterus in jaundiced infants, hemolytic anemia in G6PD deficiency).
No dose adjustment is recommended. The systemic absorption of topical dorzolamide is low (≈4%) and pharmacokinetics are not expected to change significantly in pregnancy. Use the standard adult dose: one drop in the affected eye(s) three times daily.
No standard dose adjustment recommended; pharmacokinetics altered (increased Vd, decreased Cmax) but clinical significance uncertain. Monitor for metabolic acidosis and adjust if necessary.
Dorzolamide is a topical carbonic anhydrase inhibitor used for elevated intraocular pressure. It can cause metabolic acidosis due to systemic absorption, especially in patients with renal impairment. Avoid use with oral carbonic anhydrase inhibitors to prevent additive systemic effects. Monitor for corneal edema in patients with compromised corneas. The drug may cause transient blurred vision; apply pressure over the nasolacrimal duct to minimize systemic absorption.
Acetazolamide is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and as a diuretic. Monitor serum electrolytes (especially potassium and bicarbonate) due to metabolic acidosis risk. Avoid in severe hepatic or renal impairment. Can cause paresthesias, especially in hands and feet. Use with caution in patients with sulfonamide allergy as cross-reactivity is possible but rare.
Instill one drop in the affected eye(s) three times daily, as directed.,Wash hands before and after use. Avoid touching the dropper tip to any surface.,If using other eye drops, wait at least 5 minutes between administrations.,Do not wear contact lenses during treatment; may discolor soft contact lenses.,Report eye pain, redness, vision changes, or signs of allergy (rash, itching).,May cause temporary blurred vision; do not drive or operate machinery until vision clears.,Store at room temperature, tightly closed, and protect from light.
Take exactly as prescribed; do not stop suddenly.,May cause tingling or numbness in fingers, toes, or mouth; this is usually temporary.,Drink plenty of fluids unless otherwise directed; avoid excessive alcohol.,Report unusual fatigue, muscle cramps, or rapid breathing to your doctor.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,If used for altitude sickness, start 1-2 days before ascent and continue during climb.
"Dorzolamide, a carbonic anhydrase inhibitor used for glaucoma, may theoretically inhibit the metabolism of cobicistat, a pharmacokinetic enhancer used in HIV therapy, by competing for hepatic CYP3A4 enzymes or altering renal clearance. This interaction could lead to increased cobicistat exposure, potentiating its adverse effects such as nephrotoxicity or gastrointestinal disturbances. However, clinically relevant interactions are unlikely due to dorzolamide's limited systemic absorption following ophthalmic administration."
"Chlorthalidone, a thiazide-like diuretic, and dorzolamide, a carbonic anhydrase inhibitor, both act to reduce bicarbonate reabsorption in the kidney, leading to enhanced electrolyte excretion, particularly potassium and bicarbonate. This synergistic effect can cause additive hypokalemia and metabolic acidosis, increasing the risk of cardiac arrhythmias and renal dysfunction. Concurrent use may also potentiate hypotensive effects due to volume depletion and vasodilation."
"Concurrent administration of dorzolamide, a carbonic anhydrase inhibitor, may reduce the urinary acidification necessary for methenamine's conversion to formaldehyde, the active antibacterial agent. This alkalinization of urine pH impairs the therapeutic efficacy of methenamine in treating urinary tract infections. Clinically, this can result in suboptimal bactericidal activity and potential treatment failure."
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DORZOLAMIDE HYDROCHLORIDE vs ACETAZOLAMIDE, answered by our medical review team.
DORZOLAMIDE HYDROCHLORIDE is a Carbonic Anhydrase Inhibitor that works by Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.. ACETAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DORZOLAMIDE HYDROCHLORIDE and ACETAZOLAMIDE depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DORZOLAMIDE HYDROCHLORIDE is: One drop of 2% solution in the affected eye(s) three times daily.. The standard adult dose of ACETAZOLAMIDE is: 250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DORZOLAMIDE HYDROCHLORIDE and ACETAZOLAMIDE. The risk or severity of adverse effects can be increased when Acetazolamide is combined with Dorzolamide. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DORZOLAMIDE HYDROCHLORIDE is classified as Category C. Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (ra. ACETAZOLAMIDE is classified as Category C. First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.